POLYNOVO LIMITED (PNV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PNV - POLYNOVO LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -4.11
Index: ASX200 | ASX300 | ALL-ORDS

PolyNovo is an Australian medical devices company developing and commercialising its NovoSorb technology for the treatment of burns, wounds and negative pressure wound therapy. It has been a listed company since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.375

30 Nov
2023

-0.015

OPEN

$1.39

-1.08%

HIGH

$1.41

2,360,416

LOW

$1.38

TARGET
$1.908 38.7% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PNV: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 0.7 0.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 1390.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A 0.0% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-0.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx65.2 M
Book Value Per Share xxxxxxxxxxxxxxx9.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-5.9 M
Net Profit Margin xxxxxxxxxxxxxxx-7.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-11.85 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.25 %
Return on Assets xxxxxxxxxxxxxxx-7.72 %
Return on Equity xxxxxxxxxxxxxxx-11.85 %
Return on Total Capital xxxxxxxxxxxxxxx-11.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx14 M
Total Debt xxxxxxxxxxxxxxx16 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx47 M
Price To Book Value xxxxxxxxxxxxxxx16.31

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.5 M
Capex % of Sales xxxxxxxxxxxxxxx2.34 %
Cost of Goods Sold xxxxxxxxxxxxxxx46 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx26 M
Research & Development xxxxxxxxxxxxxxx7 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxxxx xxxxxxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

26/09/2023

1

Outperform

$2.70

96.36%

PolyNovo reported sales for FY24 in the year to date were up 93%, with momentum supported by sales in new markets and increased use across different specialities.

Macquarie envisages a number of near-term positive catalysts for the company and a significant longer-term opportunity. The main catalyst will be the first half result. Outperform rating and $2.70 target maintained.

FORECAST
Macquarie forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.20 cents.
Macquarie forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.70 cents.

Morgans

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

PNV STOCK CHART

FNArena News on PNV

1
Australian Broker Call *Extra* Edition – Sep 26, 2023

Sep 26 2023 - Daily Market Reports
2
Rudi’s View: Outlook Negative, With Plenty Of Silver Linings

Sep 06 2023 - Rudi's View
3
Australian Broker Call *Extra* Edition – Aug 25, 2023

Aug 25 2023 - Daily Market Reports
4
FNArena Corporate Results Monitor – 24-08-2023

Aug 24 2023 - Australia
5
Dr Boreham’s Crucible: PolyNovo

Jul 06 2023 - Small Caps

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
2
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
3
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
4
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
5
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
6
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
7
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
8
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
10
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps